Nerandomilast, a PDE4 inhibitor, has shown significant efficacy in progressive pulmonary fibrosis (PPF), offering an ...

Nerandomilast, a PDE4B inhibitor, is a new treatment option for IPF, showing better tolerability than nintedanib and ...

The most common chronic progressive fibrosing ILD is IPF.1,2 PPF is another form of progressive fibrotic lung disease that ...

A metro woman was given a few years to live in 2022, after being diagnosed with a serious lung disease. However, thanks to a ...

The effect of pollution exposure on IPF severity and progression was not modified by MUC5B promotor polymorphism or telomere length. Long-term exposure to fine particulate matter is associated with a ...

Researchers at Tulane University have identified a potential new way to treat idiopathic pulmonary fibrosis (IPF), a deadly and currently incurable lung disease that affects more than 3 million people ...

Pulmonary fibrosis—also known in technical terms as idiopathic pulmonary fibrosis (IPF)—is a rare but life-threatening ...

United Therapeutics' stock surged after IPF trial results and what future pivotal trials could mean for investors. See here ...

Deupirfenidone 825 mg TID showed an 80.9% reduction in lung function decline rate at 26 weeks vs. placebo in IPF patients. Both deupirfenidone doses were well-tolerated, with similar GI-related ...

This condition has been described by Michael J. Stephen in his 2021 book “Breath Taking” as the “most frustrating and disheartening of all the diseases in pulmonary medicine.” Over a frighteningly ...

Munich, Germany – April 9, 2025-- Ebenbuild, a company developing personalized, AI-enabled digital twins of lungs to support clinical decisions and digital clinical trials, today announced its ...

A recent study validates that combining genetic and clinical data can predict the risk for pulmonary fibrosis in patients ...